Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company's first cyclotron facility in the Asia Pacific region (APAC).

TMS Yokohama will enable Telix to provide greater access to radiopharmaceuticals for Japanese patients, initially through clinical supply of TLX250-CDx (a kidney cancer imaging candidate), with plans to supply other Telix investigational and future commercial products, including prostate and brain cancer precision diagnostics and therapies, subject to regulatory approval.

A commemorative lecture was held to mark the occasion, delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and Professor of the Next-Generation Cancer Therapy Research Division at Osaka University, entitled: 'Trends and Challenges for the Future of Nuclear Medicine'.

Raphael Ortiz, CEO International Business and Japan President at Telix, stated, "The opening of TMS Yokohama is a significant milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and Asia Pacific. As the world's second-largest nuclear medicine market, we have always considered Japan a key country in our clinical and commercial strategy. Today demonstrates our commitment to the Japanese community, to scientific excellence, and to the well-being of patients throughout the region."

About Telix Manufacturing Solutions (TMS)

TMS is a global network of 39 manufacturing and distribution facilities across five continents, equipping Telix to deliver commercial and clinical doses to patients globally. Capabilities span isotope production, translational research and radiochemistry, antibody engineering, bioconjugation, and finished radiopharmaceutical manufacturing and distribution. Our TMS Brussels South site with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 30,000 sq ft site is one of Europe's largest radiopharmaceutical production facilities. In the United States, through our RLS network we are delivering more than 2.5 million patient doses annually. Telix's ARTMS QUANTM Irradiation System® (QIS®) advanced isotope production technology is being deployed at Telix cyclotron facilities worldwide, including select RLS radiopharmacies and TMS Brussels South and Yokohama.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com or jp.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

SOURCE Telix Pharmaceuticals Limited